Recent analyst commentary around anticipated strong earnings and faster business activity in June has pushed Progyny (PGNY) into the spotlight, with several firms issuing more positive outlooks and upgrades on the stock.

Progyny's recent analyst-inspired jump comes on top of a strong run, with a 90 day share price return of 86.08% and a 1 year total shareholder return of 39.24%. However, longer term total shareholder returns over three and five years have been negative, which suggests that momentum has picked up only more recently.

If Progyny's move has you thinking about where else growth stories could emerge in healthcare, this is a good moment to scan the market using our 40 healthcare AI stocks

After Progyny’s sharp 90 day run and fresh analyst optimism, the real tension now is whether most of the easy gains are already in the rear view mirror, or if today’s price still leaves meaningful upside once you look at valuation next.

Most Popular Narrative: 8.9% Overvalued

Progyny is trading at $32.36 compared with the most followed narrative fair value estimate of $29.73. This frames the recent rally against a slightly lower long term target built on detailed cash flow assumptions.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Curious what sits underneath that margin story and cash flow path? The narrative describes steady revenue expansion, rising profitability, and a future earnings multiple reset that may be surprising when you see the exact mix.

Result: Fair Value of $29.73 (OVERVALUED)

However, Progyny’s story could look different if employer benefit budgets tighten or if rising competition in fertility and women’s health starts to pressure pricing.

Another View: Progyny Through The Cash Flow Lens

The most followed narrative pegs Progyny as 8.9% overvalued at $32.36 versus a $29.73 fair value, but the SWS DCF model paints a very different picture. On that framework, Progyny screens as undervalued, with an estimated future cash flow value of $64.47 per share, almost double the current price. That kind of gap raises a simple question: which set of assumptions do you find more realistic for the next few years?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Progyny for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Progyny split between cautious and optimistic, this is the time to look at the data yourself and shape your own view. To see what others are finding encouraging, review the 3 key rewards

Looking for more investment ideas beyond Progyny?

If Progyny has sharpened your interest in healthcare opportunities, you can use the Simply Wall Street Screener to surface fresh stock ideas tailored to your style.

• Target potential mispricings by scanning 44 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying business strength.
• Strengthen income potential by focusing on 8 dividend fortresses that pair 5%+ yields with an emphasis on stability.
• Reduce portfolio stress by zeroing in on 79 resilient stocks with low risk scores built around resilient balance sheets and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.